For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
12
views
0
references
 Top references
cited by
59
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      200
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: not found

      Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Since almost two decades standard 1st-line chemotherapy for advanced ovarian cancer (AOC) has been a platinum/taxane combination. More recently, this general strategy has been challenged because different types of AOC may not benefit homogenously. Low-grade serous ovarian cancer (LGSOC) is one of the candidates in whom efficacy of standard chemotherapy should be revised.

          Related collections

          Author and article information

          Journal
          Journal ID (iso-abbrev): Gynecol. Oncol.
          Title: Gynecologic oncology
          Publisher: Elsevier BV
          ISSN (Electronic): 1095-6859
          ISSN (Print): 0090-8258
          Publication date (Electronic): Mar 2016
          Volume: 140
          Issue: 3
          Affiliations
          [1 ] Department of Gynecology and Gynecological Oncology, Kliniken Essen Mitte, Henricistrasse 92, 45136 Essen, Germany; Department of Gynecology, European Competence Center for Ovarian Cancer, Charite-University Medicine of Berlin, Augustenberger Platz 1, 13353 Berlin, Germany. Electronic address: jacgrab@yahoo.com.
          [2 ] Department of Gynecology and Gynecological Oncology, Kliniken Essen Mitte, Henricistrasse 92, 45136 Essen, Germany.
          [3 ] Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Oncology Department, Universite Paris Descartes, AP-HP, Hopitaux Universitaires Paris Centre, Site Hotel Dieu, Paris, France.
          [4 ] Koordinierungszentrum fuer Klinische Studien, Philipps-Universitaet Marburg, Karl-von-Frisch-Str. 4, 35043 Marburg, Germany.
          [5 ] Nordic Society of Gynaecological Oncology Group (NSGO), Department of Gynecologic Oncology, Norwegian Radium Hospital, Oslo University Hospital, PB4953 Nydalen, 0424 Oslo, Norway.
          [6 ] Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Université de Lyon-Centre Léon Bérard, Department of Medical Oncology and EA SIS, 4128 Lyon, France.
          [7 ] Department of Gynecology and Obstetrics, Klinikum Duisburg, Zu den Rehwiesen 9-11, 47055 Duisburg, Germany.
          [8 ] Gynecologic Oncology Center, Kiel, Herzog-Friedrich-Str. 21, 24103 Kiel, Germany.
          Article
          Publisher Item ID: S0090-8258(16)30020-8
          DOI: 10.1016/j.ygyno.2016.01.022
          PubMed ID: 26807488
          SO-VID: b12167bc-07ae-4c15-93a6-014092f087ea
          History

          Keywords: High-grade serous ovarian cancer,Low-grade serous ovarian cancer,Objective response,Platinum chemotherapy
          Data availability:
          Keywords: High-grade serous ovarian cancer, Low-grade serous ovarian cancer, Objective response, Platinum chemotherapy

          Comments

          Comment on this article

          scite_

          Similar content200

          See all similar

          Cited by58

          See all cited by